{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=65",
    "query": {
      "condition": "Metastatic Skin Cancer",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 2840,
    "total_pages": 284,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:29:03.086Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03007979",
      "title": "Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Malignant Tumor of Breast"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Optional research biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Research blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Circulating tumor cell blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Tumor biopsy (optional)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2017-06-15",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Lincoln, Nebraska",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03007979"
    },
    {
      "nct_id": "NCT03972046",
      "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Melanoma Stage IIIb-IVM1a",
        "Metastasis Skin",
        "Tumor Skin",
        "BRAF Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Talimogene laherparepvec (T-Vec)",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib (BRAF Inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Trametinib (MEK Inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TriHealth Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-24",
      "completion_date": "2020-02-03",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972046"
    },
    {
      "nct_id": "NCT00591734",
      "title": "RAD001 Plus Bevacizumab in Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2008-01",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 15,
      "location_summary": "Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591734"
    },
    {
      "nct_id": "NCT05508906",
      "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "ER-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palazestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Atirmociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olema Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2022-08-31",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 14,
      "location_summary": "Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05508906"
    },
    {
      "nct_id": "NCT00006035",
      "title": "Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "electroporation therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006035"
    },
    {
      "nct_id": "NCT06910657",
      "title": "IDOV-Immune for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Bladder Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Cervical Cancers",
        "Head and Neck Cancers",
        "Adrenal Gland Tumors"
      ],
      "interventions": [
        {
          "name": "IDOV-Immune (oncolytic vaccinia virus)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ViroMissile, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-08-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910657"
    },
    {
      "nct_id": "NCT06557148",
      "title": "A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Lobular Breast Carcinoma",
        "Breast Carcinoma",
        "Metastatic Breast Cancer",
        "Metastatic Lobular Breast Carcinoma",
        "Metastatic Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "18F-Fluoroestradiol PET/CT",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2024-08-13",
      "completion_date": "2027-08-13",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06557148"
    },
    {
      "nct_id": "NCT00611715",
      "title": "Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2003-11",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2012-08-09",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 9,
      "location_summary": "Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more",
      "locations": [
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Hopkinsville",
          "state": "Kentucky"
        },
        {
          "city": "Paducah",
          "state": "Kentucky"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611715"
    },
    {
      "nct_id": "NCT00717340",
      "title": "A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tivozanib (AV-951) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2009-02",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00717340"
    },
    {
      "nct_id": "NCT01844674",
      "title": "A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Melanoma, Neoplasms"
      ],
      "interventions": [
        {
          "name": "Tizanidine",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2013-09-02",
      "completion_date": "2014-08-26",
      "has_results": false,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-11-19T05:29:03.086Z",
      "location_count": 3,
      "location_summary": "Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina",
      "locations": [
        {
          "city": "Pleasant Hill",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844674"
    }
  ]
}